Survodutide
Survodutide is a dual GLP-1/glucagon receptor agonist in development for obesity that aims to reduce appetite and boost energy expenditure.
CagriSema
CagriSema is an investigational combination injection of cagrilintide and semaglutide that targets multiple appetite pathways for enhanced weight loss.
Bupropion
Bupropion is a medication that affects brain chemicals linked to appetite and cravings, and may support weight loss when used as part of a comprehensive programme.
Tesofensine
An investigational weight loss tablet that affects three brain chemicals to suppress appetite and support metabolism.
Setmelanotide (Imcivree)
An injectable medication that treats severe obesity caused by specific rare genetic conditions by restoring the brain’s fullness signal.
SGLT-2 Inhibitors and Weight
Diabetes medications that promote weight loss by causing the kidneys to excrete excess sugar through urine, resulting in a net calorie loss of 200-300 kcal daily.
Orforglipron
An oral GLP-1 receptor agonist in development that mimics natural hunger-regulating hormones without injections.
Cagrilintide
A long-acting amylin analogue given as a weekly injection to enhance feelings of fullness and reduce food intake.
Retatrutide
Retatrutide is an investigational triple-hormone agonist that achieved up to 24% body weight loss in clinical trials, approaching surgical-level results.
Dulaglutide (Trulicity)
Dulaglutide (Trulicity) is a once-weekly GLP-1 injection for type 2 diabetes that also supports meaningful weight loss.